XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals using its PASylation® Technology

FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany, a privately owned biopharmaceutical company, announced today that they have entered into a license agreement with MSD Animal Health (known as Merck Animal Health in the USA and Canada) to develop PASylated biopharmaceuticals for use in animal health. This license agreement follows a research collaboration between […]

XL-protein and YEDA sign business collaboration agreement to commercialize PASylated interferon superagonist

FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014 – Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSα8 – which has been jointly developed […]

XL-protein announces publication of key scientific data on its PASylation® technology

FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced today that key scientific data have been published in the journal Protein Engineering, Design & Selection (2013, Vol. 26, No. 8, pp. 489–501, 2013). The Open Access Publication “PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins” is also available […]